Eli Lilly Plans to Buy Ajax Therapeutics for Up to $2.3 Billion

• Ajax's lead asset AJ1-11095 is a once-daily oral treatment in early-stage testing for previously treated myelofibrosis patients, a rare chronic blood cancer affecting bone marrow
• Clinical proof-of-concept data is expected in 2026, after which Lilly plans to advance the drug into registrational trials
• The $2.3 billion deal structure includes upfront cash and contingent payments based on achieving specific clinical and regulatory milestones

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion

Eli Lilly announced on April 27 its plan to acquire privately held Ajax Therapeutics for up to $2.3 billion in cash, expanding its oncology portfolio with a focus on rare blood cancers.

Key Transaction Details:

• Deal structure includes an upfront payment plus milestone-based payments tied to clinical and regulatory achievements
• All-cash transaction for the privately held biotech company

Lead Asset:

Ajax's primary candidate, AJ1-11095, is an experimental once-daily oral treatment currently in early-stage clinical trials. The drug targets myelofibrosis, a rare chronic blood cancer characterized by scar tissue buildup in bone marrow that disrupts normal blood cell production. The therapy is being tested in previously treated patients.

Timeline and Development:

Clinical proof-of-concept data is expected in late 2026. Following successful data presentation, Lilly plans to rapidly advance AJ1-11095 into registrational clinical trials, leveraging its expertise in blood cancer treatments.

Strategic Rationale:

Jacob Van Naarden, President of Lilly Oncology, emphasized the company's commitment to delivering important new medicines to patients and hematologists, positioning this acquisition as part of Lilly's broader oncology strategy.

Market Implications:

The acquisition strengthens Lilly's position in the rare blood cancer treatment space and demonstrates continued consolidation in the biotech sector. The milestone-based payment structure reflects standard risk-sharing mechanisms for early-stage assets, with significant payments contingent on successful clinical and regulatory outcomes. This deal adds to Lilly's growing oncology pipeline as the pharmaceutical giant continues strategic expansion beyond its core diabetes and obesity franchises.